{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:17Z","timestamp":1786119557074,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1097\/aco.0b013e32833f9ea6","type":"journal-article","created":{"date-parts":[[2010,9,16]],"date-time":"2010-09-16T07:11:32Z","timestamp":1284621092000},"page":"722-725","source":"Crossref","is-referenced-by-count":5,"title":["The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery?"],"prefix":"10.1097","volume":"23","author":[{"given":"Alessandro","family":"Squizzato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Romualdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Dentali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210129","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"R2-10-20210129","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/archinte.1991.00400050081016","article-title":"A population-based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study","volume":"151","author":"Anderson","year":"1991","journal-title":"Arch Intern Med"},{"key":"R3-10-20210129","first-page":"197","article-title":"Practice patterns for deep vein thrombosis prophylaxis in minimal access surgery","volume":"49","author":"Beekman","year":"2006","journal-title":"Can J Surg"},{"key":"R4-10-20210129","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1378\/chest.08-0673","article-title":"New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Weitz","year":"2008","journal-title":"Chest"},{"key":"R5-10-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200464001-00002","article-title":"Current options in the prevention of thromboembolic disease","volume":"64","author":"Ansell","year":"2004","journal-title":"Drugs"},{"key":"R6-10-20210129","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","article-title":"Oral direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases","volume":"27","author":"Turpie","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl 1","key":"R7-10-20210129","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0049-3848(03)00249-4","article-title":"The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review","volume":"109","author":"Gustafsson","year":"2003","journal-title":"Thromb Res"},{"key":"R8-10-20210129","first-page":"905","article-title":"BIBR-1048 Boehringer Ingelheim","volume":"3","author":"Mungall","year":"2002","journal-title":"Curr Opin Invest Drugs"},{"key":"R9-10-20210129","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R10-10-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors development","volume":"48","author":"Eriksson","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R12-10-20210129","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, noninferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"R13-10-20210129","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R14-10-20210129","first-page":"1","article-title":"The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery","volume":"2","author":"Ginsberg","year":"2009","journal-title":"J Arthroplasty"},{"key":"R15-10-20210129","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1160\/TH08-07-0493","article-title":"Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis","volume":"101","author":"Wolowacz","year":"2009","journal-title":"Thromb Haemost"},{"key":"R16-10-20210129","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003495-200666110-00001","article-title":"Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopedic surgery","volume":"66","author":"Eriksson","year":"2006","journal-title":"Drugs"},{"key":"R17-10-20210129","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety pharmacodynamics and pharmacokinetics of BAY39-7959, an oral direct factor Xa inhibitor: after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R18-10-20210129","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/13543784.15.8.843","article-title":"Novel factor Xa inhibitors for the prevention and treatment of thromboembolic diseases","volume":"15","author":"Kubitza","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"R19-10-20210129","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"R20-10-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind randomized controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"R21-10-20210129","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"R22-10-20210129","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"R23-10-20210129","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies","volume":"6","author":"Wong","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R24-10-20210129","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for the thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N Engl J Med"},{"key":"R25-10-20210129","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 1","key":"R26-10-20210129","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.ijsu.2008.12.020","article-title":"Thromboprophylaxis in day surgery","volume":"6","author":"Squizzato","year":"2008","journal-title":"Int J Surg"}],"container-title":["Current Opinion in Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ACO.0b013e32833f9ea6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:34:26Z","timestamp":1786041266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001503-201012000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/aco.0b013e32833f9ea6","relation":{},"ISSN":["0952-7907"],"issn-type":[{"value":"0952-7907","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}